bioAffinity Technologies partners with AvMEDICAL to distribute CyPath Lung test across federal healthcare market
BIAF•bioAffinity Technologies entered a nationwide federal healthcare distribution agreement with veteran-owned AvMEDICAL for its CyPath Lung test, which the companies presented to more than 300 attendees at the 2026 NAVREF Annual Conference.
1. Federal distribution agreement
bioAffinity Technologies partnered with veteran-owned AvMEDICAL to distribute its CyPath Lung cancer test across the federal healthcare market. The agreement aims to expand access through AvMEDICAL’s procurement channels, contracting expertise and customer relationships.
2. Test presentation
The companies jointly presented CyPath Lung to more than 300 attendees at the 2026 NAVREF Annual Conference. The noninvasive, sputum-based test is intended to complement imaging in lung cancer assessment, with a focus on veteran screening needs.
